OS Therapies (NYSE:OSTX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of OS Therapies (NYSE:OSTX) in a research note released on Monday,Benzinga reports. The firm currently has a $20.00 target price on the stock.

Separately, Lake Street Capital began coverage on OS Therapies in a research note on Wednesday, April 2nd. They set a “buy” rating and a $19.00 target price for the company. Three investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, OS Therapies presently has an average rating of “Buy” and a consensus target price of $18.00.

OS Therapies Stock Down 8.2%

NYSE OSTX opened at $1.56 on Monday. The stock has a market cap of $43.83 million and a PE ratio of -1.81. OS Therapies has a fifty-two week low of $1.12 and a fifty-two week high of $7.00. The business has a 50 day moving average price of $1.76 and a two-hundred day moving average price of $2.08.

Insider Transactions at OS Therapies

In related news, major shareholder Shalom Auerbach sold 82,000 shares of the stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $2.00, for a total value of $164,000.00. Following the completion of the transaction, the insider owned 2,664,199 shares in the company, valued at $5,328,398. This trade represents a 2.99% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On OS Therapies

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC boosted its holdings in shares of OS Therapies Inc (NYSE:OSTX) by 172.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 300,000 shares of the company’s stock after acquiring an additional 189,956 shares during the quarter. CM Management LLC owned 1.38% of OS Therapies worth $462,000 at the end of the most recent quarter.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.